Answers are grounded in this paper and cite their sources.
Randomized trial reveals no difference in health outcomes in type 1 diabetes participants, suggesting safety of immunotherapy.
OBJECTIVE: Long-term side effect surveillance after immunotherapy clinical trial participation in individuals with or at risk of type 1 diabetes is needed. RESEARCH DESIGN AND METHODS: Participants from 14 randomized controlled trials (47%) joined the Long-term Investigative Follow-up in Type 1 Diabetes TrialNet or Immune Tolerance Network Type 1 Diabetes Extension Study, and 98% answered at least one health-related outcomes question. RESULTS: Participants were observed for a median of 1.78 (interquartile range 0.89-4.04) years after original trial completion and, in some, up to 18 years. There were no differences in the frequency of self-reported health outcomes, including moderate to severe hypoglycemia events, hospitalizations, serious infections (including COVID-19 infection), new allergic reactions, autoimmune disease, and cancer incidence, between those receiving active and placebo therapy (n = 209-473 responses per question; P > 0.05 for all). CONCLUSIONS: We observed no differences in self-reported health outcomes between those who received active immunotherapy versus placebo. Continued long-term follow-up of immunotherapy trial participants is essential.
No takes yet. Share an insight, caveat, or question.
Jacobsen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: